Metformin C4 Health (Metformin Hydrochloride)

Metformin reduces hepatic gluconeogenesis, thereby lowering the amount of glucose released by the liver. It also enhances insulin‑mediated glucose uptake in muscle and adipose tissue, increasing peripheral insulin sensitivity. These actions collectively improve overall glycemic control without stimulating insulin secretion.

The dosage of Metformin C4 Health is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and titration schedule.

Metformin’s pregnancy category is not definitively established. Use during pregnancy or lactation should be decided by a qualified healthcare provider after weighing potential benefits against risks. Breastfeeding mothers should consult their physician before using metformin.

To request Metformin C4 Health, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Metformin belongs to the biguanide class and is generally first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycemia compared with sulfonylureas or insulin. Its mechanism differs from DPP‑4 inhibitors, GLP‑1 agonists, and SGLT2 inhibitors, which act on incretin pathways or renal glucose reabsorption.

Store at below 25 °C in a dry place, protected from moisture and direct sunlight. Keep the tablets in the original container with the lid tightly closed until use.

Metformin C4 Health is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water; they should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious adverse reaction is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or conditions predisposing to hypoxia. Prompt medical attention is required if symptoms such as unexplained fatigue, rapid breathing, or abdominal pain develop.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in individuals with known hypersensitivity to metformin or other biguanides.